{
    "id": 1836,
    "fullName": "CDKN2A loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "CDKN2A loss indicates loss of the CDKN2A gene, mRNA and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1029,
        "geneSymbol": "CDKN2A",
        "terms": [
            "CDKN2A",
            "ARF",
            "CDK4I",
            "CDKN2",
            "CMM2",
            "INK4",
            "INK4A",
            "MLM",
            "MTS-1",
            "MTS1",
            "P14",
            "P14ARF",
            "P16",
            "P16-INK4A",
            "P16INK4",
            "P16INK4A",
            "P19",
            "P19ARF",
            "TP16"
        ]
    },
    "variant": "loss",
    "createDate": "09/19/2014",
    "updateDate": "09/19/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10252,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of multiple cancer cell lines harboring CDKN2A loss and in Cdkn2a-depleted transformed cells in culture (PMID: 26140595).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18862,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (TAPUR), patients with pancreatic cancer harboring a CDKN2A mutation or loss of CDKN2A (n=10) did not demonstrate an objective response or stable disease at 16 weeks when treated with single therapy, Ibrance (palbociclib), demonstrating a median progression-free survival of 7.2 weeks and an overall survival of 12.4 weeks (JCO Precision Oncology, Aug 14, 2019; NCT02693535).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16508,
                    "pubMedId": null,
                    "title": "Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study",
                    "url": "https://ascopubs.org/doi/10.1200/PO.19.00124"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1061,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of Gemzar (gemcitabine) in pancreatic cancer cells with CDKN2A loss in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 1510,
                "therapyName": "Gemcitabine + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8540,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line with CDKN2A loss demonstrated sensitivity to Mekinist (trametinib) in culture, resulting in inhibition of cell growth (PMID: 27488531).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2270,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an orthotopic mouse model treated with ZK 304709 demonstrated an 80% tumor growth reduction in neuroendocrine tumor cells with CDKN2A loss (PMID: 18829975).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 2735,
                "therapyName": "ZK 304709",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2949,
                    "pubMedId": 18829975,
                    "title": "The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18829975"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7583,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited expression of phosphorylated Rb and growth of chordoma cell lines with CDKN2A loss and loss of p16 protein expression in culture (PMID: 26183925).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3302,
                "name": "chordoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4578,
                    "pubMedId": 26183925,
                    "title": "Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26183925"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18864,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (TAPUR), patients with biliary cancer harboring a CDKN2A mutation or loss of CDKN2A (n=10) did not demonstrate an objective response or stable disease at 16 weeks when treated with single therapy, Ibrance (palbociclib), demonstrating a median progression-free survival of 7.3 weeks and an overall survival of 11.1 weeks (JCO Precision Oncology, Aug 14, 2019; NCT02693535).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 4607,
                "name": "biliary tract cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16508,
                    "pubMedId": null,
                    "title": "Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study",
                    "url": "https://ascopubs.org/doi/10.1200/PO.19.00124"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2269,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Milciclib (PHA-848125AC) resulted in tumor regression in glioma cell line xenograft models with CDKN2A loss (PMID: 23347136).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 2654,
                "therapyName": "Milciclib",
                "synonyms": null
            },
            "indication": {
                "id": 3073,
                "name": "brain glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2840,
                    "pubMedId": 23347136,
                    "title": "Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23347136"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17260,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (TAPUR), Ibrance (palbociclib) treatment resulted in a disease control rate of 29% (7/28, 1 partial response, 6 stable disease at 16 weeks) in patients with non-small cell lung cancer harboring CDKN2A loss or mutations, with a median progression-free survival of 9.7 weeks and a median overall survival of 20.6 months (J Clin Oncol 37, 2019 (suppl; abstr 9041); NCT02693535).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15295,
                    "pubMedId": null,
                    "title": "Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.",
                    "url": "http://abstracts.asco.org/239/AbstView_239_252743.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2935,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Ibrance (palbociclib) resulted in and stable disease in 50% (8/16) of non-small cell lung cancer patients with CDKN2A loss (J Clin Oncol 32:5s, 2014 (suppl; abstr 8077)).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3540,
                    "pubMedId": null,
                    "title": "A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A.",
                    "url": "http://meetinglibrary.asco.org/content/135087-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2268,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines with CDKN2A loss demonstrated a greater sensitivity to Alvocidib (flavopiridol) as compared to melanoma cell lines positive for CDKN2A (PMID: 12777976).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 628,
                "therapyName": "Alvocidib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2838,
                    "pubMedId": 12777976,
                    "title": "The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12777976"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7585,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Abemaciclib (LY2835219) inhibited growth of chordoma cell lines with CDKN2A loss and loss of p16 protein expression in culture (PMID: 26183925).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 3302,
                "name": "chordoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4578,
                    "pubMedId": 26183925,
                    "title": "Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26183925"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2267,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, renal cell carcinoma cell lines with CDKN2A loss were sensitive to Palbociclib (PD-0332991) (PMID: 23898052).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2948,
                    "pubMedId": 23898052,
                    "title": "PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23898052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1062,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of GSK461364 in pancreatic cancer cells with CDKN2A loss in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 1511,
                "therapyName": "GSK461364 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8537,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line deficient for CDKN2A demonstrated resistance to treatment with Ibrance (palbociclib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1064,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) antagonized the activity of HMN-214 in pancreatic cancer cell lines with CDKN2A loss in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 1514,
                "therapyName": "HMN-214 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1699,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Pimasertib acted synergistically to decrease proliferation of pancreatic cancer cell lines with loss of CDKN2A and upregulation of CCNE1 and CCND1in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 2016,
                "therapyName": "Palbociclib + Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1059,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, pancreatic cancer cell lines with a loss of CDKN2A, upregulation of CCNE1 and CCND1 conferred resistance to Ibrance (palbociclib) treatment in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1071,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Selumetinib (AZD6244) acted synergistically to decrease proliferation of pancreatic cancer cell lines with loss of CDKN2A and upregulation of CCNE1 and CCND1 in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 1517,
                "therapyName": "Palbociclib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1066,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and BEZ235 acted synergistically to decrease proliferation of pancreatic cancer cell lines with loss of CDKN2A and upregulation of CCNE1 and CCND1 in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 1515,
                "therapyName": "BEZ235 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1068,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Apitolisib (GDC-0980) acted synergistically to decrease proliferation and survival of pancreatic cancer cells with loss of CDKN2A and upregulation of CCNE1 and CCND1 in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 1516,
                "therapyName": "GDC-0980 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1060,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Adrucil (fluorouracil) acted synergistically to decrease proliferation and survival of pancreatic cancer cell lines with a loss of CDKN2A and upregulation of CCNE1 and CCND1 in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 1509,
                "therapyName": "Fluorouracil + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1067,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and AZD0855 acted synergistically to decrease proliferation of pancreatic cancer cell lines with loss of CDKN2A and upregulation of CCNE1 and CCND1 in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 1520,
                "therapyName": "AZD8055 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2266,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Abemaciclib (LY2835219) resulted in a partial response in a melanoma patient with CDKN2A loss and NRAS mutation (PMID: 27217383).",
            "molecularProfile": {
                "id": 6894,
                "profileName": "CDKN2A loss NRAS mut"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2947,
                    "pubMedId": null,
                    "title": "A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer",
                    "url": "http://meetinglibrary.asco.org/content/111069-132"
                },
                {
                    "id": 6356,
                    "pubMedId": 27217383,
                    "title": "Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217383"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2923,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Mekinist (trametinib) induced tumor regression in a mouse melanoma model expressing NRAS Q61K and harboring CDKN2A loss (PMID: 22983396).",
            "molecularProfile": {
                "id": 10733,
                "profileName": "CDKN2A loss NRAS Q61K"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3528,
                    "pubMedId": 22983396,
                    "title": "Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22983396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3791,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SBI-0640726 delayed tumor growth of melanomas in mice with a genetic background of NRAS Q61K and CDKN2A loss (PMID: 26603897).",
            "molecularProfile": {
                "id": 10733,
                "profileName": "CDKN2A loss NRAS Q61K"
            },
            "therapy": {
                "id": 3306,
                "therapyName": "SBI-0640756",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5879,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Alpelisib (BYL719) and Kisqali (ribociclib) resulted in tumor regression in patient-derived xenograft (PDX) models of estrogen-receptor positive breast cancer harboring ESR1 Y537S and loss of both CDKN2A and CDKN2B, with improved efficacy over either agent alone (PMID: 27020857).",
            "molecularProfile": {
                "id": 21976,
                "profileName": "CDKN2A loss CDKN2B loss ESR1 Y537S"
            },
            "therapy": {
                "id": 3969,
                "therapyName": "Alpelisib + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5881,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Falsodex (fulvestrant), Alpelisib (BYL719), and Kisqali (ribociclib) resulted in rapid tumor reduction in PDX models of breast cancer cells harboring ESR1 Y537S and concomitant loss of CDKN2A and CDKN2B (PMID: 27020857).",
            "molecularProfile": {
                "id": 21976,
                "profileName": "CDKN2A loss CDKN2B loss ESR1 Y537S"
            },
            "therapy": {
                "id": 2317,
                "therapyName": "Alpelisib + Fulvestrant + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7431,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a squamous non-small cell lung carcinoma patient with KRAS wild-type and loss of CDKN2A demonstrated a partial response when treated with Abemaciclib (LY2835219) (PMID: 27217383).",
            "molecularProfile": {
                "id": 25455,
                "profileName": "CDKN2A loss KRAS wild-type"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6356,
                    "pubMedId": 27217383,
                    "title": "Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217383"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8417,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with AT7519 in patient derived acral lentigineous melanoma cells co-harboring CDK4 amplification and loss of CDKN2A resulted in inhibition of cell proliferation in culture and suppression of tumor growth in the patient derived xenograft models (J Clin Oncol 34, 2016 (suppl; abstr 9512)).",
            "molecularProfile": {
                "id": 26316,
                "profileName": "CDK4 amp CDKN2A loss"
            },
            "therapy": {
                "id": 2727,
                "therapyName": "AT7519",
                "synonyms": null
            },
            "indication": {
                "id": 6367,
                "name": "acral lentiginous melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6643,
                    "pubMedId": null,
                    "title": "Prevalent aberrations of CDK4 pathway in acral melanoma and implications for targeted therapy",
                    "url": "http://meetinglibrary.asco.org/content/167622-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15763,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) treatment resulted in cell cycle arrest, leading to tumor growth suppression in patient-derived xenograft (PDX) models of nasopharyngeal carcinoma harboring CCND1 amplification and CDKN2A loss (PMID: 30236142).",
            "molecularProfile": {
                "id": 26317,
                "profileName": "CCND1 amp CDKN2A loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 9261,
                "name": "nasopharynx carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13785,
                    "pubMedId": 30236142,
                    "title": "Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30236142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8418,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acral lentiginous melanoma cells co-harboring CCND1 amplification and loss of CDKN2A demonstrated inhibition of cell proliferation when treated with AT7519 in culture (J Clin Oncol 34, 2016 (suppl; abstr 9512)).",
            "molecularProfile": {
                "id": 26317,
                "profileName": "CCND1 amp CDKN2A loss"
            },
            "therapy": {
                "id": 2727,
                "therapyName": "AT7519",
                "synonyms": null
            },
            "indication": {
                "id": 6367,
                "name": "acral lentiginous melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6643,
                    "pubMedId": null,
                    "title": "Prevalent aberrations of CDK4 pathway in acral melanoma and implications for targeted therapy",
                    "url": "http://meetinglibrary.asco.org/content/167622-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9355,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited tumor growth and improved survival in patient-derived intracranial xenografts models of RB-proficient glioblastoma harboring homozygous deletion of the CDKN2A and CDKN2B (PMID: 20354191).",
            "molecularProfile": {
                "id": 26829,
                "profileName": "CDKN2A loss CDKN2B loss RB1 pos"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4520,
                    "pubMedId": 20354191,
                    "title": "Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20354191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15795,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Buparlisib (BYL719) and Ibrance (palbociclib) resulted in increased tumor growth inhibition compared to either agent alone in patient-derived xenograft (PDX) models of lung squamous cell carcinoma harboring PIK3CA E542K or E545K mutations with p16 (CDKN2A) loss, including models that also had either PIK3CA amplification or PTEN loss (PMID: 30093452).",
            "molecularProfile": {
                "id": 31219,
                "profileName": "CDKN2A loss PIK3CA act mut"
            },
            "therapy": {
                "id": 7736,
                "therapyName": "Buparlisib + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13808,
                    "pubMedId": 30093452,
                    "title": "Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15799,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Buparlisib (BYL719) and Ibrance (palbociclib) resulted in increased tumor growth inhibition compared to either agent alone in a patient-derived xenograft (PDX) model of lung squamous cell carcinoma harboring PIK3CA E542K and PTEN loss, with p16 (CDKN2A) loss (PMID: 30093452).",
            "molecularProfile": {
                "id": 31222,
                "profileName": "CDKN2A loss PIK3CA E542K PTEN loss"
            },
            "therapy": {
                "id": 7736,
                "therapyName": "Buparlisib + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13808,
                    "pubMedId": 30093452,
                    "title": "Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15798,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Buparlisib (BYL719) and Ibrance (palbociclib) resulted in increased tumor growth inhibition compared to either agent alone in patient-derived xenograft (PDX) models of lung squamous cell carcinoma harboring PIK3CA E545K and PIK3CA amplification, with p16 (CDKN2A) loss (PMID: 30093452).",
            "molecularProfile": {
                "id": 31223,
                "profileName": "CDKN2A loss PIK3CA E545K PIK3CA amp"
            },
            "therapy": {
                "id": 7736,
                "therapyName": "Buparlisib + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13808,
                    "pubMedId": 30093452,
                    "title": "Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15800,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Buparlisib (BYL719) and Ibrance (palbociclib) resulted in increased tumor growth inhibition compared to either agent alone in a patient-derived xenograft (PDX) model of lung squamous cell carcinoma harboring PIK3CA E542K and PIK3CA amplification, with p16 (CDKN2A) loss (PMID: 30093452).",
            "molecularProfile": {
                "id": 31224,
                "profileName": "CDKN2A loss PIK3CA E542K PIK3CA amp"
            },
            "therapy": {
                "id": 7736,
                "therapyName": "Buparlisib + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13808,
                    "pubMedId": 30093452,
                    "title": "Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18296,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PALOMA-1/TRIO-18), CCND1 amplification and/or CDKN2A loss did not correlate with response to addition of Ibrance (palbociclib) to Femara (letrozole) in patients with estrogen receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.37 and 0.19 (p=0.13) in patients with or without CCND1 amplification and/or CDKN2A loss, respectively (PMID: 25524798; NCT00721409).",
            "molecularProfile": {
                "id": 33130,
                "profileName": "CDKN2A loss ESR1 pos"
            },
            "therapy": {
                "id": 2922,
                "therapyName": "Letrozole + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16122,
                    "pubMedId": 25524798,
                    "title": "The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25524798"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1804,
            "profileName": "CCNE1 over exp CDKN2A loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1806,
            "profileName": "CDKN2A loss",
            "profileTreatmentApproaches": [
                {
                    "id": 7818,
                    "name": "CDK4/6 Inhibitor",
                    "profileName": "CDKN2A loss"
                },
                {
                    "id": 7817,
                    "name": "CDK Inhibitor (Pan)",
                    "profileName": "CDKN2A loss"
                },
                {
                    "id": 7816,
                    "name": "CDK6 Inhibitor",
                    "profileName": "CDKN2A loss"
                },
                {
                    "id": 7819,
                    "name": "CDK4 Inhibitor",
                    "profileName": "CDKN2A loss"
                }
            ]
        },
        {
            "id": 2398,
            "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 6894,
            "profileName": "CDKN2A loss NRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 10733,
            "profileName": "CDKN2A loss NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21976,
            "profileName": "CDKN2A loss CDKN2B loss ESR1 Y537S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25455,
            "profileName": "CDKN2A loss KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26316,
            "profileName": "CDK4 amp CDKN2A loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26317,
            "profileName": "CCND1 amp CDKN2A loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26829,
            "profileName": "CDKN2A loss CDKN2B loss RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26834,
            "profileName": "CDK4 pos CDKN2A loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26835,
            "profileName": "CDK6 amp CDKN2A loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26836,
            "profileName": "CDKN2A loss CDKN2C loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31219,
            "profileName": "CDKN2A loss PIK3CA act mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31222,
            "profileName": "CDKN2A loss PIK3CA E542K PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31223,
            "profileName": "CDKN2A loss PIK3CA E545K PIK3CA amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31224,
            "profileName": "CDKN2A loss PIK3CA E542K PIK3CA amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33130,
            "profileName": "CDKN2A loss ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}